Machine learning and natural language processing (NLP) approach to predict early progression to first-line treatment in real-world hormone receptor-positive (HR+)/HER2-negative advanced breast cancer patients

2021 ◽  
Vol 144 ◽  
pp. 224-231
Author(s):  
Nuria Ribelles ◽  
Jose M. Jerez ◽  
Pablo Rodriguez-Brazzarola ◽  
Begoña Jimenez ◽  
Tamara Diaz-Redondo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Natural Language Processing ◽  
Language Processing ◽  
Line Treatment ◽  
Breast Cancer Patients ◽  
First Line ◽  
Hormone Receptor Positive ◽  
Early Progression ◽  
First Line Treatment

scholarly journals Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

ISRN Oncology ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-7 ◽  
Author(s):  
Athina Stravodimou ◽  
Khalil Zaman ◽  
Ioannis A. Voutsadakis
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Median Overall Survival ◽  
Objective Response ◽  
Metastatic Breast ◽  
Line Treatment ◽  
Breast Cancer Patients ◽  
Single Institution ◽  
First Line ◽  
First Line Treatment

Background. We report our experience with vinorelbine, a widely used chemotherapeutic, in unselected metastatic breast cancer patients treated in clinical routine. Patients and Methods. The data of all patients with metastatic breast cancer receiving vinorelbine with or without trastuzumab during a six year period were reviewed. Patients received vinorelbine intravenous 25–30 mg/m2 or 60–80 mg/m2 orally in days 1 and 8 of a 21 day cycle. Results. Eighty-seven women were included. Sixty-two patients received vinorelbine alone and 25 patients received vinorelbine in combination with trastuzumab. In 67 patients this was the first line treatment for metastatic disease and in 20 patients it was 2nd or later line of treatment. The median TTP was six months (range: 1–45). The median overall survival was 11.5 months (range: 1–83). Seventy patients were evaluable for response. In patients receiving first line treatment 44.4% had a response while in the second and subsequent lines setting 12.5% of patients responded (P=0.001). Objective response was obtained in 63.6% of patients receiving concomitant trastuzumab and in 25% of patients receiving vinorelbine alone (P=0.0002). Conclusion. This study confirms a high disease control rate. Response rate and TTP were superior in first line treatment compared to subsequent lines.

Sign in / Sign up

Export Citation Format

Share Document